Who makes Leuprolide Oral Tablet 10-mg BID?

Leuprolide Oral Tablet 10-mg BID is developed by Enteris BioPharma Inc..

What development phase is Leuprolide Oral Tablet 10-mg BID in?

Leuprolide Oral Tablet 10-mg BID is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Leuprolide Oral Tablet 10-mg BID

Enteris BioPharma Inc. · Phase 2 active Small molecule

At a glance

Generic name	Leuprolide Oral Tablet 10-mg BID
Also known as	Ovarest™ 10.0 mg
Sponsor	Enteris BioPharma Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of Pharmacokinetic/Pharmacodynamic Profile of Orally Administered Leuprolide in Healthy Female Volunteers (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Leuprolide Oral Tablet 10-mg BID CI brief — competitive landscape report
Leuprolide Oral Tablet 10-mg BID updates RSS · CI watch RSS
Enteris BioPharma Inc. portfolio CI